Severe cutaneous adverse reactions (SCARs) encompass a heterogeneous group of delayed hypersensitivity reactions, which are most frequently caused by drugs. Our understanding of several aspects of SCAR syndromes has evolved considerably over the last decade. This review explores evolving knowledge of the immunopathogenic mechanisms, pharmacogenomic associations, in vivo and ex vivo diagnostics for causality assessment, and medication cross-reactivity data related to SCAR syndromes. Given the rarity and severity of these diseases, multidisciplinary collaboration through large international, national and/or multicentre networks to collect prospective data on patients with SCAR syndromes should be prioritized. This will further enhance a systematized framework for translating epidemiological, clinical and immunopathogenetic advances into preventive efforts and improved outcomes for patients.
• The pathogenesis underlying T-cell-mediated delayed hypersensitivity reactions involves interactions between small-molecule drugs, human leucocyte antigen (HLA) class I molecules and T-cell receptors.
What does this study add?
• Pharmacogenomic discoveries associating severe T-cell-mediated drug hypersensitivity syndromes have created the promise of prevention. This has led to universal HLA screening or HLA genotyping before drug prescription.
• Knowledge has evolved of the immunopathogenesis of SCARs and key novel and nonmutually exclusive mechanisms by which drugs activate T cells.
• In vivo and ex vivo diagnostics are being increasingly employed to aid causality assessment.
• Knowledge of cross-reactivity between structurally related medications is still rudimentary, but may avoid precipitating subsequent severe episodes and minimize unwarranted restriction of therapeutic options.
Severe cutaneous adverse reactions (SCARs) encompass a heterogeneous group of delayed hypersensitivity reactions, most frequently caused by drugs, which are associated with significant morbidity and mortality. 1, 2 SCARs include StevensJohnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS or HSS) and acute generalized exanthematous pustulosis (AGEP). 3 The clinical, biochemical and histological characteristics of these syndromes are summarized in Table 1 . Our understanding of several aspects of SCAR syndromes has evolved considerably over the last decade. The recent 2016 U.K. guidelines on the management of SJS/TEN in adults highlighted many areas of evolving research. 4 The aim of this article is to provide a complementary review of emerging immunopathogenic mechanisms, established pharmacogenomic associations, in vivo and ex vivo causality assessment tools and medication cross-reactivity data related to SCAR syndromes.
Immunopathogenesis of severe cutaneous adverse reactions
Medications are the causative agents in > 85% of SCARs in adults, 5 with frequently implicated drugs being antimicrobials, aromatic antiepileptic drugs and antimetabolite agents -particularly allopurinol and its derivatives. 4, 5 Regardless of the causal medications, T-cell-mediated delayed hypersensitivity reactions, triggered by interactions between small-molecule drugs, human leucocyte antigen (HLA) class I molecules and T-cell receptors, underlie the pathogenesis of most SCARs. Increasing knowledge suggests that carriage of specific HLA risk allele(s) is a necessary but not sufficient factor in initiating the immunopathogenesis cascade. 6 Currently, three nonmutually exclusive models have been proposed: the hapten/prohapten, pharmacological interaction and altered peptide repertoire models (Fig. 1) . The resultant effector immune mechanisms in turn contribute to the characteristic clinical manifestations of each condition. These mechanisms include eosinophil-mediated injury in DRESS, 7 CD8
+ cytotoxic T-cell-mediated injury in SJS/TEN 4 and the cytotoxic peptide 15-kDa granulysin that has been identified as a key molecule produced by CD8 + T cells, natural killer (NK) T cells and NK cells and is responsible for the disseminated keratinocyte death in SJS/TEN (Table 1) . 8 Of note, the study of Bellon et al. suggests that the overexpression of endogenous damage-associate molecular patterns or alarmins in SJS/TEN supports the involvement of the innate immune system in the pathogenesis of delayed hypersensitivity reactions, suggesting an extension of the T-cell-mediated hypothesis. 9 Indeed, several innate immune components have been investigated in the aetiopathogenesis of SJS/TEN. Morel et al. revealed that the innate receptor CD94/NKG2C is expressed by NK cells and cytotoxic T lymphocytes and might be involved in triggering degranulation in response to HLA-E in patients with SJS/TEN. 10 A further study by the same authors determined that upregulation of the innate immune molecules, a-defensins 1-3, in T cells may be involved in the pathogenesis of SJS/TEN. 11 There is accumulating research to suggest that humoral and cellular components of the innate immune response may be involved in the pathogenesis of delayed cutaneous hypersensitivity reactions. 12 Higher plasma concentrations of the drug and/or its metabolites, caused by the individual's in vivo absorption, distribution, metabolism and elimination (ADME) enzyme activities, or by way of drug-drug interactions, increase the risk for many hypersensitivity reactions. 13, 14 This apparent dose dependency seen in severe T-cell-mediated adverse drug reactions supports that small molecules are noncovalently interacting with an immune receptor. For instance, elevated serum levels of oxypurinol, an active metabolite of allopurinol, which has a long plasma half-life, increase the risk of allopurinol hypersensitivity. 14 Impaired renal function leading to high plasma concentrations of oxypurinol is also directly correlated with disease severity and mortality. 14 Historically, certain types of trimethoprim-sulfamethoxazole hypersensitivity reactions were more likely in those with N-acetyltransferase 2 slow-acetylator genotypes. 15 Collectively, the paradigm has been shifting towards an interplay between ADME enzymatic activities and immunological mechanisms being responsible for the initiation of hypersensitivity responses, 16 further triggered by yet to be determined insults (such as viral infections), leading to polarization towards distinct cytokine profiles and effector pathways. Further studies are required to explore this evolving concept of hypersensitivity and drug-concentration-dependent relationships.
The role of herpesvirus reactivation
Heterologous immunity is a long-standing concept that has recently gained renewed interest to explain both individual susceptibility and tissue specificity of SCARs. In this model, the effector memory T cells generated during the course of a remote infection and maintained by latency or re-exposure to the infectious agent cross-react with drug-modified proteins, thereby highlighting the role of infectious agents, such as chronic persistent DNA viruses including human herpesviruses (HHVs), in SCAR pathogenesis. 16 The concept of heterologous immunity in the immunopathogenesis of SCARs should not be confused with the reactivation of HHVs, in particular HHV-6, which is known to be associated with DRESS. [17] [18] [19] [20] Reactivation of Epstein-Barr virus (EBV), cytomegalovirus (CMV), HHV-6 and HHV-7 has been reported to occur in DRESS syndrome typically 2-3 weeks following the original syndrome and in the absence of re-exposure to the drug. It appears to correlate with the immune dysregulation occurring during DRESS syndrome and, in particular, regulatory T-cell dysfunction. The reported proportion of patients with HHV-6 reactivation in DRESS varies according to the specific implicated drug and is between 36% and 62%. 18, 21 HHV-6 reactivation, as measured by a rise in HHV-6 immunoglobulin G titres and plasma HHV-6 DNA levels, typically occurs 2-3 weeks after the onset of the rash. 22 This temporal association suggests a complex interaction between HHV and the immunopathogenesis of DRESS. 22 Furthermore, reactivation of HHV has also been associated with the development of more severe disease. 19, [21] [22] [23] [24] The development of autoimmune diseases, such as systemic lupus erythematosus, type 1 diabetes mellitus and autoimmune thyroiditis, is a late complication of DRESS that has been associated with herpesvirus reactivation. 20, [25] [26] [27] Reactivation of the other herpesviruses, which include HHV-7, EBV and CMV, has also been reported to occur in association with DRESS. 22, 28, 29 Indeed, sequential reactivation of herpesviruses during the course of DRESS has been described in a similar sequence to that in graft-versus-host disease: HHV-6 and/or EBV, followed by HHV-7 and subsequently by CMV. 29 Viral reactivation may also explain the prolonged clinical symptoms, multiorgan involvement and systemic inflammation following discontinuation of the offending drug. 22, [29] [30] [31] DRESS has been reported in the setting of immune reconstitution inflammatory syndrome (IRIS). IRIS describes an inflammatory processes that occurs soon after the initiation of highly active antiretroviral therapy in patients with HIV and is associated with an increase in CD4 + cell count and/or decrease in HIV viral load. 32 IRIS occurs as a result of immune recovery and results in the host recognizing pre-existing or latent infections. 33 DRESS may be considered a form of immune constitution whereby unregulated immune activation occurs against reactivated herpesviruses.
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However, for SJS/TEN, there is weaker evidence, only at case report level, for its association with HHV-6 reactivation. Furthermore, this could also be secondary to phenotypic misattribution of viral reactivation associated with profound immunosuppression secondary to the protracted clinical course and significant courses of immunosuppressants, such as ciclosporin used in SJS/TEN. 34, 35 The role of CMV has been proposed in the development of AGEP; 36 however, evidence from European Study of Severe Cutaneous Adverse Reactions (Euro-SCAR) failed to find such an association. 37 Testing for herpesvirus reactivation in SCAR syndromes may assist in clarifying the diagnosis in cases where the cutaneous and other clinical findings are nonspecific, and may also be of prognostic value.
21,31,38
Recent advances in pharmacogenomics in severe cutaneous adverse reactions Individuals with certain HLA genotypes carry higher risks of developing SCAR syndromes. Over the last decade, clinically significant pharmacogenomic associations have been discovered, leading to specific recommendations regarding HLA genotyping before prescription of drugs to reduce the risks in susceptible populations. However, for common causal medications, antibiotics in particular, very few clinically meaningful HLA associations exist. 39 Medications that are considered to have strong pharmacogenomic associations with severe Tcell-mediated adverse drug reactions are presented in Table 2 . Routine genetic screening prior to their prescription has already or may soon become the standard of clinical practice.
Abacavir
Abacavir, an antiretroviral drug used in combination therapy to treat HIV, is associated with HSS in 5% (range 0-14%) of patients. 40 The hypersensitivity syndrome associated with abacavir is differentiated from DRESS/DIHS in that the median time to presentation with fever and malaise is 8 days, with latency periods as short as 1 day. Rash, which does not occur in up to 30% of cases, is often a late feature of the presentation. The skin involvement in abacavir HSS is typically a mildto-moderate exanthem without evidence of blistering or epidermal detachment. Dechallenge after withdrawal of drug occurs rapidly with disappearance of the fever, malaise and even skin rash within 72 h of abacavir withdrawal. HLA-B *57:01 was found to be a significant risk allele for abacavir HSS by two independent groups. 41, 42 The lack of specificity of clinical symptoms and signs associated with abacavir HSS in HIV-positive individuals led to a high clinical false-positive rate and an apparent lack of sensitivity of the HLA-B 
Carbamazepine
Carbamazepine is an aromatic amine anticonvulsant and is associated with cutaneous adverse reactions in up to 10% of patients. 49 Although two-digit HLA associations had been previously described between allopurinol SJS/TEN and sulfa antimicrobial SJS/TEN, the association between HLA-B *15:02 and carbamazepine SJS/TEN in a Taiwanese population was the first-four digit association for SJS/TEN and the strongest overall for SJS/TEN in the literature to date. 50 showed a stronger association with DRESS (pooled OR 13Á2, 95% CI 8Á4-20Á8, P < 0Á001) than with SJS/TEN (pooled OR 3Á94, 95% CI 1Á4-11Á5, P = 0Á01). 58, 63 This effect was particularly noted in populations where HLA-B *15:02 carriage is prevalent, where it is likely that the strong association between HLA-B *15:02 and carbamazepine SJS/TEN overshadows that of HLA-A *31:01. In contrast, in Europeans, the higher frequency of the HLA-A *31:01 allele appears to overshadow the effect of the uncommon HLA-B *15:02 allele. 47, 51 Regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency have issued recommendations regarding genotyping before initiation of carbamazepine in certain at-risk populations. 64 Genetic testing for HLA-B *15:02 is recommended in Han Chinese, Southeast Asian and South Asian populations or in patients whose ethnic origin is unknown. HLA-A *31:01 testing may be considered in patients of all ancestries; however, there is no current recommendation for routine screening for HLA-A *31:01 before initiation of carbamazepine therapy. In patients who are positive for HLA-B *15:02, alternatives to carbamazepine should be used, preferably avoiding all aromatic amine anticonvulsants, as SJS/TEN has been more weakly associated with HLA-B *15:02 with these drugs in Southeast Asian patients. In the case of HLA-A *31:01 positivity, ideally an alternative first-line medication to carbamazepine should be used in carbamazepine-naive individuals, unless there are no identifiable alternatives, in which case patients should be followed with extremely close monitoring for the first signs of evolving SCAR. 58 
Allopurinol
Allopurinol accounts for up to 5% of all cases of SCAR. 65 An association between allopurinol-induced SCAR (SJS/TEN and HSS phenotypes) and the HLA-B *58:01 genotype was first described in a Taiwanese Han Chinese population. 66 
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A modelling study from Singapore showed that routine genetic screening to prevent an episode of SCAR, even in high-risk populations, did not appear to be cost-effective. 76 The extreme short-and long-term morbidity and mortality that are in particular associated with SJS/TEN, the lack of comparably inexpensive treatment options with allopurinol, the development of newer and less expensive molecular assays for HLA-B *58:01 and the availability of a prospective screening study suggesting a significantly reduced incidence of allopurinol SCAR with HLA-B *58:01 screening in Taiwan suggest that further attention and implementation of HLA-B *58:01 screening may be warranted. 77 Causality assessment through clinical, in vivo and ex vivo testing Assigning drug causality is often difficult in SCAR syndromes, especially when multiple agents are implicated, in particular antimicrobials. 78 Conversely, in situations of a single implicated drug (e.g. carbamazepine or allopurinol), utilization of appropriate clinical algorithms is often sufficient to assign causality, 5, 18, 79 especially in histologically confirmed cases. 80, 81 Drug causality may be clinically established through several different validated methods or algorithms, each with own strengths and limitations (Table 3) . Nonetheless, in vivo and ex vivo diagnostics are being increasingly employed to identify causality and aid management of patients with SCARs. 82 Guidelines exist for the recommended concentrations of drugs to be used in in vivo testing for delayed hypersensitivity, 83, 84 although universal consensus has not been established.
Patch testing
Patch testing involves the application of an implicated and/or potentially cross-reactive drug with a control vehicle (petroleum jelly) to the skin for 48 h, 82 which is subsequently read after 48-96 h and if possible 7 days. The safety of patch testing in SCARs has been increasingly demonstrated. [85] [86] [87] [88] [89] [90] [91] Systemic (but nonlife-threatening) reactions have been reported infrequently with patch testing, although mostly for antituberculosis drugs in patients with HIV. [92] [93] [94] [95] [96] The recommendations have been to perform skin testing at least 6 weeks after resolution of the SCAR. 97 The sensitivity of patch testing appears highest for abacavir HSS (87%) 43, 44 and DRESS (31Á6-58%) and lowest for SJS/TEN (20-24%) and AGEP (18%). 85, 86, 90 The sensitivity also appears to be affected by the investigated drug: it is highest for abacavir, anticonvulsants and beta-lactam antibiotics (in particular for abacavir, 87%) 87 and amoxicillin (up to 44Á4%), and lowest for vancomycin (9Á1%), trimethoprim-sulfamethoxazole (8Á6%), macrolides (4Á8%), hepatitis C antivirals 98 and cephalosporins (4Á4%). 85 Oral provocation after a negative patch test should be used with caution in patients with SCARs, considering the low sensitivity of patch testing.
Intradermal testing
Intradermal testing (IDT), utilizing 0Á02-0Á05 mL of the highest nonirritant concentration of drug, has been reported in DRESS and other SCAR phenotypes in a number of small series. 86, [99] [100] [101] IDT with delayed readings has been utilized extensively for T-cell-mediated hypersensitivity, in particular for non-SCAR phenotypes related to beta-lactams. 102, 103 IDT avoids the inconvenience of patch testing, and reactions will often occur within 6-24 h. Barbaud et al. demonstrated in a small cohort of predominately beta-lactam SCARs that IDT appeared to have a greater sensitivity than patch testing when performed following negative patch testing, and was not associated with adverse events. 86 Guidelines also support the use of IDT following negative patch testing in patients with SCAR, outside of SJS/TEN. 83 IDT is often limited by the availability of a sterile injectable formulation of the investigated drug. Like patch testing, oral provocation testing after negative IDT should be undertaken with caution.
Ex vivo diagnostics
The stimulation of patient peripheral blood mononuclear cells (PBMCs) to measure T-cell responses in the setting of drugassociated SCAR has been increasingly investigated in research and clinical settings. While responses have been detected up to 20 years after the index event, a blood sample from 'acute bleeds' or in the early recovery phase is likely to display greater sensitivity. [104] [105] [106] The lymphocyte transformation test Collection of specific data points followed by problem-solving operations resulting in an objective assessment of probability lower rates have still been noted in lamotrigine-mediated SJS. 130 Indeed, Polak et al. compared the lymphocyte proliferation assay (LPA) against combination IFN-c and IL-4 drug ELISpot assays in patients with delayed-type drug hypersensitivity reactions in the acute phase. 131 In their study, the assays demonstrated test specificities of 95%, 83% and 92% for LPA, IFN-c and IL-4, respectively. During acute drug hypersensitivity reactions, the sensitivity of combined measurement of drug-specific IFN-c and IL-4 cytokines was greater than that of LPA (82% vs. 50%). Thus, these investigators determined that in vitro assays of drug-specific IFN-c and IL-4 production may be more sensitive than LPA for the detection of drug-specific T cells in the acute setting. 131 Furthermore, a recent study by
Haw et al. concluded that cytokine assays (IFN-c and IL-4) are superior to LPA in identifying the causative drug in the paediatric population; however, these investigators suggested that when combined, they offer even greater utility in the diagnosis and postrecovery of delayed-type hypersensitivity reactions. 132 The sensitivity and hence negative predictive value of ex vivo testing in the future is likely to be enhanced by concurrent utilization of flow cytometry and intracellular cytokine staining methods. 118, [133] [134] [135] [136] The importance of drug cross-reactivity between structurally related drugs Structurally related drugs can cause cross-reactions with SCARs. Although the specific epitopes remain elusive with regards to drug-self peptide responses, it is recognized that the immune system may recognize structural similarities. Knowledge regarding the likelihood of cross-reactivity between drugs is important, as exposure to structurally similar compounds after an index reaction can precipitate another severe episode. On the contrary, excessive avoidance of medications with low risk of cross-reactivity can lead to unwarranted restriction on therapeutic options that can adversely impact upon clinical care.
Beta-lactams
All beta-lactams (penicillins, cephalosporins, carbapenems and monobactams) share the core beta-lactam structure but with differing side chains (Fig. 2) . Evolving evidence to date suggests that side-chain structures are commonly implicated in beta-lactam cross-reactivity for most immediate and delayed reactions. Table 4 provides a list of commonly prescribed beta-lactams that share similar side-chain structures. Cephalosporins have two side chains, R1 and R2. However, R2 is lost during hydrolysis.
Cephalosporins R1 side chains of cephalosporins (Fig. 2) are highly conserved and have been demonstrated to promote cross-reactions with penicillins containing similar structures. This is particularly true between aminopenicillins (amoxicillin, ampicillin and bacampicillin) and aminocephalosporins (cephalexin and cefaclor), with recent studies demonstrating that the cross-reactivity rates between the amino compounds may be as high as 18Á7%. 137, 138 On the contrary, patients with delayed aminopenicillin allergy have recently been shown to have complete absence of cross-reactivity and good tolerance to therapeutic challenge to nonaminocephalosporins (cefuroxime and ceftriaxone). 137 Overall, low rates of cross-reactivity exist between penicillins and third-and fourth-generation cephalosporins with dissimilar side-chain structures (1Á1% vs. 10Á9% for first-and second-generation cephalosporins that share similar side chains). 138 Furthermore, El-Ghaiesh et al. carried out an interesting in vitro study in eight patients with cystic fibrosis with delayed hypersensitivity reactions to piperacillin, compared with five tolerant controls. 113 They demonstrated the critical role of drug-specific CD4 + and CD8 + T-cell clones in pathogenesis, which did not cross-react to a multitude of penicillins and cephalosporins including those that share similar side chains to piperacillin (e.g. cefoperazone). This study highlights the drug-specific nature of T-cell-mediated hypersensitivity reactions, as well as the highly complex nature of cross-reactivity to other beta-lactams, with some unknown mechanisms in addition to 'structural similarities' likely further contributing to their pathogenesis. 113 
Carbapenems and monobactams
A cross-reactivity rate of 5Á5% to imipenem has been previously reported in penicillin-allergic patients. 139 A more recent study involving 204 patients demonstrated that none of the patients with delayed penicillin hypersensitivity cross-reacted to imipenem, meropenem or ertapenem, and all tolerated therapeutic doses of drug challenge. 140 In view of the reportedly low (< 1%) rates of cross-reactivity to carbapenems in patients with immediate penicillin hypersensitivity reactions, 141 ,142 the true cross-reactivity rates in delayed reactions are likely very low (< 1%), and therefore carbapenems may be judiciously considered in patients who have limited therapeutic options. In contrast, virtually zero per cent cross-reactivity to aztreonam has been consistently demonstrated in patients with delayed penicillin hypersensitivity reactions. 137, 143 The only caveat is that aztreonam should be avoided in patients with ceftazidime allergy due to side-chain similarities. It should also be noted that although cross-reactivity rates between penicillins and later-generation cephalosporins or carbapenems are low, the vast majority of patients included in these studies had benign skin reactions, and few patients with definitive SCAR phenotypes were represented. As such, considerable caution should be taken when prescribing beta-lactam antibiotics to patients with SCAR.
Aromatic anticonvulsants
Commonly prescribed aromatic anticonvulsants include carbamazepine, oxcarbazepine, lamotrigine, phenytoin and phenobarbital. 144 Cross-reactivity between these structurally related aromatic anticonvulsants was originally thought to be mediated by arene oxides, toxic metabolites produced through cytochrome P450 pathway. 145, 146 However, it is now clear that poor metabolizers (e.g. of CYP2C9*3) are at higher risk for SCARs associated with some anticonvulsants such as phenytoin. 147 Earlier studies suggested that approximately 70% of users will experience some degree of cross-reactivity between aromatic anticonvulsants. 146, [148] [149] [150] There is also evidence suggesting that HLA-B *15:02 and other B75-serotype HLA alleles confer risk of developing SJS/TEN to other aromatic anticonvulsants, although to a much lesser degree than with carbamazepine. 151, 152 What is currently unclear is the extent to which HLA crossreactivity occurs, as cases of HLA-B *15:02-positive individuals who have reacted to one aromatic amine anticonvulsant but tolerated another (despite the association of HLA-B *15:02 with all aromatic amine anticonvulsant SCARs) have been well described. Additionally, Seitz et al. noted that 21Á7% of patients with carbamazepine hypersensitivity also displayed cross-reactivity to tricyclic antidepressants. 150 However, this has not been substantiated as an effect that is seen in vivo, and in the case of HSS to carbamazepine, recommendations would not dictate avoidance of tricyclic antidepressants. In patients 
Conclusions and future directions
Recent advances in the knowledge of SCAR syndromes have provided us with a better understanding of immunopathogenic mechanisms, including the potential role of pre-existing crossreactive T-cell responses to viral infections; the discovery of important pharmacogenomic associations, which have defined the standard of care; the use of clinical and laboratory methods for causality assessment and the knowledge of drug cross-reactivity mechanisms. Further knowledge is required on how precisely drugs activate T cells, the pathomechanism for the generally very low positive predictive value of an HLA risk allele for a specific drug toxicity, more specific pharmacogenomic associations and future mechanistic information including cellular and molecular signatures. This will be key for preclinical prediction and prevention of drug toxicity, as well as for enabling personalized approaches to prevention, early intervention and treatment of high-morbidity and high-mortality diseases such as SJS/TEN. As highlighted in this review, numerous aspects of SCAR syndromes merit further interdisciplinary research. Finally, given the overall rarity but high morbidity and mortality of SCARs, collaboration through large international, national and multicentre networks to collect prospective data and biobank samples will further enhance a systematized framework for translating discovery into prevention and improved outcomes for patients.
